Advertisement
News
Subscribe to Drug Discovery & Development News

The Lead

New Front in War on Alzheimer’s, Other Protein-Folding Diseases

October 17, 2014 | Comments

A surprise discovery that overturns decades of thinking about how the body fixes proteins that come unraveled greatly expands opportunities for therapies to prevent diseases such as Alzheimer’s and Parkinson’s, which have been linked to the accumulation of improperly folded proteins in the brain. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

U.S. Monitors Health Care Worker Aboard Cruise Ship

October 17, 2014 1:43 pm | by Jim Kuhnhenn | Comments

A cruise ship with a Dallas health care worker aboard who is being monitored for signs of Ebola did not receive clearance to dock in Cozumel, Mexico, a day after Belize refused to let the passenger leave the vessel. Read more...

TOPICS:

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

TOPICS:

UN: We botched response to the Ebola outbreak

October 17, 2014 11:15 am | by Maria Cheng - AP Medical Writer - Associated Press | Comments

The World Health Organization has admitted that it botched attempts to stop the now-spiraling Ebola outbreak in West Africa, blaming factors including incompetent staff and a lack of information. Read more...

TOPICS:
Advertisement

Anoro's COPD Drug Shows Improved Lung Function

October 17, 2014 11:07 am | Comments

Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta. Read more...                                     

TOPICS:

Pharmacyclics' Non-Chemo Treatment Approved in Europe

October 17, 2014 10:54 am | Comments

Pharmacyclics Inc. announced that the European Commission (EC) has granted marketing approval for Imbruvica (ibrutinib) throughout the 28 member states of the European Union (EU). Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe. Read more...

TOPICS:

A Look At Latest Ebola Developments

October 17, 2014 10:40 am | Comments

The nation's top health officials tried to assure Congress that they can halt the spread of the Ebola virus in the U.S. despite mistakes that allowed two nurses to get the infection from a patient. Read more...

TOPICS:

Scientific Breakthrough May Help Design Future Antibiotics

October 17, 2014 10:33 am | Comments

Scientists have used computer simulations to show how bacteria are able to destroy antibiotics – a breakthrough which may help develop drugs which can effectively tackle infections in the future. Read more...

TOPICS:

FDA Votes to Keep Boxed Warning on Chantix

October 17, 2014 10:26 am | Comments

Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information. Read more...

TOPICS:
Advertisement

Big Step in Battling Bladder Cancer

October 16, 2014 3:06 pm | Comments

The millions of people worldwide who suffer from the painful bladder disease known as interstitial cystitis (IC) may soon have a better, long-term treatment option, thanks to a controlled-release, implantable device invented by MIT researchers. Read more...

TOPICS:

Big Step in Battling Bladder Disease

October 16, 2014 1:33 pm | Comments

Novel device that stays in the bladder and slowly releases drugs sells to pharmaceutical giant. Read more...                                                             

TOPICS:

MIT, MGH Partner to Address Clinical Medicine Challenges

October 16, 2014 1:08 pm | Comments

A novel partnership between MIT and Massachusetts General Hospital (MGH) is addressing three major challenges in clinical medicine. Read more...                                          

TOPICS:

Eli Lilly's Lechleiter Honored as Watanabe Life Sciences Champion of the Year

October 16, 2014 12:43 pm | Comments

BioCrossroads awarded John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, with the August M. Watanabe Life Sciences Champion of the Year Award, a prestigious honor named in tribute to BioCrossroads' late first Chairman. Read more...

TOPICS:

Personalized Cellular Therapy Achieves Remission in Leukemia Patients

October 16, 2014 12:36 pm | Comments

Ninety percent of children and adults with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. Read more...

TOPICS:

Scientists Develop Decoy Drug to Form New Connections

October 16, 2014 12:18 pm | Comments

A team of Stanford Bio-X scientists has restored the ability of adult mice to form new connections in the brain. If the finding works in people, it has the potential to help adults recover from stroke and forms of blindness or to prevent the loss of connections in Alzheimer's disease. Read more...

TOPICS:

Moderna, Sweden Universities Collaborate on Drug Discovery

October 16, 2014 10:48 am | Comments

Moderna Therapeutics announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics(TM) enable the in vivo production of both intracellular proteins and secreted proteins. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading